IST Biosciences is committed to leveraging breakthrough binding molecule development technology to significantly improve the diagnosis and treatment of medical disease thereby improving medical outcomes and quality of life for humankind.  

Key to this model is IST Biosciences patent-pending technology for the rapid identification and isolation of high affinity, high specificity DNA aptamers, which will ultimately supplant antibodies used in today’s biomarker assays. These aptamers are capable of binding to disease markers, toxins and diseased cells enabling highly sensitive detection and consequent early diagnosis of disease.    Further advantages of aptamers over antibodies include lower cost, faster production, longer shelf life and higher affinity/specificity.  Lastly their smaller size (lower molecular weight) makes them a more qualified candidate to detect smaller molecules such as peptides which hold significant promise as biomarkers for cancer detection and treatment.  These aptamers can be further utilized without modification for highly efficient (high specificity and sensitivity) detection of proteins on commonly used platforms such as ELISA, pRT-PCR and Surface Plasmon Resonance (SPR).  This technology presents a unique and sustainable competitive advantage for IST Biosciences while its dedicated and experienced management team knows what it takes to foster a new technology-based endeavor such as this.